23 January 2025
Coulter Partners secures CEO Placement for NeoPhore

Coulter Partners successfully completed a search assignment for NeoPhore Limited and is pleased to announce the placement of Michael Shih as Chief Executive Officer (CEO) and Board of Director.
NeoPhore, a small molecule neoantigen immuno-oncology company, is developing a pipeline of highly validated, first-in-class small molecule drugs targeting proteins across the DNA mismatch repair (MMR) pathway to improve the efficacy and durability of revolutionary immunotherapies to treat cancer.
Michael Shih is a highly experienced business development executive with nearly 20 years of success in driving strategic growth. He has a proven track record in leading and executing successful business development transactions, including licensing, mergers & acquisitions, and strategic collaborations.
Robert James, Chairman of the Board, NeoPhore, said: “Michael joins at an exciting stage in NeoPhore’s development having raised a significant Series B financing round which was supported by Bristol Myers Squibb. As we move closer to being a clinical Company, Michael’s experience as a corporate development leader in pharma and biotech will be instrumental in driving NeoPhore’s next phase of growth.”
Michael Shih, newly appointed Chief Executive Officer and Board of Director, NeoPhore commented: “NeoPhore’s differentiated approach to targeting the MMR pathway has huge potential to treat cancer. I am looking forward to working with the highly experienced NeoPhore team, who are all clearly aligned to advance the Company’s pipeline.”
----

Michael Shih, Chief Executive Officer of NeoPhore
Michael Shih has nearly 20 years of experience in business development, licensing and mergers & acquisitions. He was most recently Vice President of Corporate Development at Kite Pharma, where he led multiple business development opportunities for the Company. Before this, Michael was Senior Vice President, Head of Business Development at Biogen, leading the team responsible for sourcing, structuring and executing strategic collaborations and merger and acquisition opportunities. Prior to joining Biogen, Michael was Vice President and Head of Global Transactions at Sanofi, where he oversaw the structuring and negotiation of business development transactions across Sanofi’s business units. Michael has also held senior business development roles at Epizyme, Forest Laboratories and Eisai.
About NeoPhore
For more information, please visit www.neophore.com
About Coulter Partners
www.coulterpartners.com
Related
-
Events
19th Bioshares Biotech Summit
07 August 2025 – 08 August 2025
-
Company News
Coulter Partners: Fostering Digital Health connections on the Seine
09 July 2025
-
Thought Leadership
Building better Boards: Key challenges and insights for scaling companies
07 July 2025 | Author: Ian Coyne
-
Company News
Coulter Partners joins key discussion on HealthTech Boards at NHS Innovation Accelerator day
02 July 2025